Casey Hager, MD
Cardiovascular Disease · South Charleston, WVNPI 1497918452
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,400 of the $20,072 with a category attached, or 61.8%. Novartis accounts for 69.2% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $13,920 and has fallen 91.4% since, to $1,194 in 2025. Among cardiovascular disease clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $44.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$14K
- Boehringer Ingelheim$884
- Johnson & Johnson$639
- AstraZeneca$555
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$432
- Amgen$394
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$12,40062%
- Travel & lodging$3602%
- Food & beverage$7,25236%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 76 | $13,893 |
| Boehringer Ingelheim | 56 | $884 |
| Johnson & Johnson | 45 | $639 |
| AstraZeneca(2 entities) | 26 | $555 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 45 | $432 |
| Amgen | 25 | $394 |
| Novo Nordisk | 24 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $340 |
| Esperion Therapeutics, Inc. | 15 | $297 |
| Amarin Pharma, Inc. | 15 | $223 |
| Bayer | 12 | $202 |
| Lilly USA, LLC | 6 | $199 |
| Mylan Specialty L.p. | 10 | $181 |
| Pfizer | 7 | $140 |
| Exact Sciences | 6 | $131 |
| Sunovion Pharmaceuticals Inc. | 7 | $103 |
| Merck | 5 | $103 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Tactile Systems Technology Inc | 2 | $83 |
| GSK | 5 | $80 |
| Medtronic | 2 | $72 |
| Insmed, Inc. | 4 | $69 |
| Dexcom, Inc. | 3 | $63 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| AbbVie | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Lundbeck LLC | 3 | $41 |
| Verona Pharma, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Averitas Pharma Inc. | 2 | $32 |
| Eisai Inc. | 2 | $28 |
| Apria Healthcare LLC | 1 | $23 |
| Teleflex LLC | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Heartflow, Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Ambu Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,072 in reported general payments places this provider in the 90th percentile of 100 cardiovascular disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 164 | $141,510 |
| EntrestoSacubitril/Valsartan | 110 | $96,590 |
| EliquisApixaban | 101 | $96,203 |
| JardianceEmpagliflozin | 90 | $69,795 |
| FarxigaDapagliflozin Propanediol | 42 | $41,782 |
| Repatha SureclickEvolocumab | 31 | $26,446 |
| BrilintaTicagrelor | 31 | $19,582 |
| VascepaIcosapent Ethyl | 28 | $17,791 |
| Ranolazine ErRanolazine | 198 | $7,074 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $4,729 |
| Metoprolol Succinate | 496 | $4,528 |
| Ezetimibe | 398 | $4,218 |
| Icosapent Ethyl | 14 | $3,362 |
| Atorvastatin Calcium | 273 | $2,049 |
| Rosuvastatin Calcium | 241 | $2,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $639 | $141,510164 claims |
| NovartisEntresto | $13,893 | $96,590110 claims |
| PfizerEliquis | $140 | $96,203101 claims |
| Boehringer IngelheimJardiance | $884 | $69,79590 claims |
| AstraZenecaFarxiga, Brilinta | $555 | $61,36473 claims |
| Esperion Therapeutics, Inc.Nexlizet | $297 | $4,72912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 100 cardiovascular disease providers in West Virginia.
Other cardiovascular disease in South Charleston
- Mohammad YousafSouth Charleston$34K
- Sarah RinehartCharleston$303K
- Maninder BediWeirton$230K
- Partho SenguptaMorgantown$131K
- Kofi OseiHuntington$87K
- Esam BaryunHuntington$55K
- Madhavi KadiyalaMorgantown$29K
- Rameez SayyedHuntington$21K
- David CampseyMorgantown$21K
- Daniel JovanovichWeirton$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.